Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Novartis

Status and phase: Completed; Phase 2

Conditions: Photosensitive Epilepsy

Treatments: Drug: Placebo; Drug: BGG492

Study type: Interventional

Funder types: Industry

Identifiers

NCT00784212

CBGG492A2203

2007-005418-38 (EudraCT Number)

Details and patient eligibility

About

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Enrollment: 13 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of photosensitive epilepsy

Exclusion criteria

• inconsistent photoparoxysmal response when stimulated by photic stimulation

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

13 participants in 3 patient groups

Cohort 1

Experimental group

Treatment:

Drug: BGG492

Drug: BGG492

Cohort II

Experimental group

Treatment:

Drug: BGG492

Drug: BGG492

Cohort III

Experimental group

Treatment:

Drug: Placebo